Clinical Trials Logo

MSI-H Colorectal Cancer clinical trials

View clinical trials related to MSI-H Colorectal Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04301557 Active, not recruiting - Clinical trials for MSI-H Colorectal Cancer

PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

Start date: July 31, 2020
Phase: Phase 2
Study type: Interventional

PD1 antibody is now recommended for dMMR/MSI-H metastatic colorectal cancer patients as second line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and is also recommended as an alternative choice for unresectable locally advanced colon cancer. Thus, this study will investigate the efficacy and toxicity of combination strategy using PD1 antibody and chemoradiotherapy for dMMR/MSI-H locally advnaced colorectal cancer patients.

NCT ID: NCT03983993 Active, not recruiting - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

NIPAVect
Start date: October 15, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well niraparib and panitumumab work in treating patients with colorectal cancer that has spread to other places in the body. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and panitumumab may work better in treating patients with colorectal cancer.